Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer

About Prolocor

Prolocor is a private, pre-revenue diagnostics company pioneering a precision medicine approach to cardiovascular disease (CVD). Its core technology is a diagnostic test measuring platelet surface FcγRIIa expression, a biomarker implicated in amplifying platelet activation and thrombosis. The company is actively validating this biomarker through multiple observational clinical trials in areas like myocardial infarction, stroke, and cancer-associated thrombosis. If successful, Prolocor's test could address a significant unmet need for tools that personalize antiplatelet therapy and improve CVD outcomes.

Therapeutic Areas